Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
Date:10/27/2008

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.

The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF).

The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall Institute (WEHI) that antagonism of G-CSF or its receptor could ameliorate inflammatory conditions such as rheumatoid arthritis.

Under the terms of the restructure, CSL will now take full control of the program, including development and commercialisation of any potential drugs arising from the program. In return, MuriGen will receive certain payments - the details of which are undisclosed.

Dr Nick Samaras, MuriGen's Chief Executive Officer, said, "We are extremely pleased that the further development of the G-CSF inflammatory disease program will be conducted by an Australian biopharmaceutical partner with the expertise and capability that CSL provide. This partnership is another major milestone for MuriGen and is further evidence of the high quality portfolio the company has in-licensed from the Walter and Eliza Hall Institute. MuriGen will continue to focus on its other programs, including the development of a novel class of antiapoptotic compounds."

"This is an important step in the translation of the Institute's intellectual property," explains Dr Julian Clark, Head of Business Development at WEHI. Clark continues, "Starfish Ventures' investment in MuriGen enabled us to bring this project to a stage where CSL can now use their considerable resources and track record to progress development towards the clinic."

Dr Andrew Cuthbertson, Director of R&D at CSL said, "The G-CSF inflammatory disease project is an excellent example of the strength of Australian medical research. We look forward to a continuing collaboration with our academic colleagues as we take this program into early stage development."

About MuriGen Therapeutics

MuriGen Therapeutics is an Australian-based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research and four of its leading scientists. MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients. Further information about MuriGen Therapeutics can be found at http://www.murigen.com.au

About WEHI

The Walter and Eliza Hall Institute of Medical Research (WEHI) is one of the world's leading medical research centres. WEHI's international reputation has been built upon major contributions to immunology, haematology, cancer, malaria and autoimmune diseases, including diabetes, multiple sclerosis, coeliac disease and rheumatoid arthritis. Over many decades, advances and discoveries in these areas have led to significant benefits for patients throughout the world. WEHI is in the front line of the biotechnology revolution, using advances in genetics, bioinformatics and structural biology to help develop individualised therapies and more effective drugs. Further information about WEHI can be found at http://www.wehi.edu.au

Further information:

Dr Nick Samaras

Chief Executive Officer

MuriGen Pty Ltd

+61 3 9345 2115

Or

Dr Julian Clark

Head Business Development

Walter and Eliza Hall Institute of Medical Research

+61 3 9345 2612


'/>"/>
SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... dedicated to finding cures for inflammatory bowel diseases (IBD), and ReachMD , ... deliver exclusive content to ReachMD learners. , The partnership, which launched in ...
(Date:3/29/2017)... Texas, March 29, 2017  Vermillion, Inc. (NASDAQ: ... disease, reported on its results for the fourth ... "2016 marked a pivotal year for ... guideline inclusion, international distribution agreements, major reimbursement progress ... network payer agreements. In addition we cleared our ...
(Date:3/29/2017)... , March 29, 2017 "Surging application ... deployed by the government are expected to drive the ... The gesture recognition market is expected to be ... CAGR of 29.63% between 2017 and 2022. The touchless ... billion by 2022, growing at a CAGR of 17.44% ...
(Date:3/29/2017)... , March 29, 2017 WuXi Biologics, ... company dedicated to biologics and a WuXi AppTec ... 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, ... Excellence Awards aims to recognize outstanding leaders and ... Featuring top bioprocessing and biomanufacturing experts in the ...
Breaking Biology Technology:
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
Breaking Biology News(10 mins):